ESMO 2019: Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma
Posted: Monday, October 21, 2019
Among patients with advanced renal cell carcinoma who did not undergo upfront cytoreductive nephrectomy, those who received first-line avelumab and axitinib experienced greater primary tumor shrinkage than patients treated with sunitinib. These findings from a subgroup analysis of the phase III JAVELIN Renal 1010 trial were presented at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona (Abstract 908PD) and simultaneously published in Annals of Oncology.
“This is the first report of the efficacy of immuno-oncology [plus] tyrosine kinase inhibitor therapy on the primary tumor in the context of metastatic renal cell carcinoma and provides insight into future neoadjuvant strategies in advanced renal cell carcinoma,” Laurence Albiges, MD, PhD, of the Institut Gustave Roussy, Villejuif, France, and colleagues concluded.
The study authors randomly assigned 886 patients with clear cell advanced renal cell carcinoma and no systemic therapy to receive first-line avelumab plus axitinib (n = 443) or sunitinib (n = 444). Of the 886 patients, 179 (20.2%) did not undergo upfront cytoreductive nephrectomy. In the avelumab-and-axitinib arm, 55 of 90 patients had renal target lesions, compared with 62 of 89 patients in the sunitinib arm.
Of patients with renal target lesions who did not undergo upfront cytoreductive nephrectomy, more patients treated with the combination therapy experienced at least a 30% reduction in the primary target lesion from baseline than patients treated with sunitinib (34.5% vs. 9.7%). The median time to at least 30% shrinkage was also shorter among patients treated with the combination therapy than with sunitinib (4.4 months vs. 7.1 months).
Disclosure: The study authors’ disclosure information may be found at cslide.ctimeetingtech.com.